

## **NEWLY DIAGNOSED COVID-19 PATIENTS MAY BE ELIGIBLE TO PARTICIPATE IN A CLINICAL RESEARCH STUDY**

Newly diagnosed COVID-19 patients who have not yet received treatment may be eligible to participate in a randomized (by chance) clinical research study at Rutgers Cancer Institute of New Jersey, Robert Wood Johnson University Hospital in New Brunswick, and University Hospital in Newark. The research study is examining the drugs hydroxychloroquine (FDA approved for the treatment of malaria and autoimmune diseases) and the antibiotic azithromycin. The purpose of the research is to determine if the combined drugs work better than hydroxychloroquine alone when treating COVID-19 positive patients.



### **ELIGIBILITY REQUIREMENTS INCLUDE:**

- A positive test result for COVID-19
- Must be 18 years or older
- Ability to swallow medication orally.

Participants may receive study treatment for 10 days and will remain on the study for a follow-up of six months. Possible benefits of taking part in this study may include improvement of your condition.

**To see if you are eligible to participate, contact Rutgers Cancer Institute's Office of Human Research Services at 732-235-7356 or email [statewide\\_research@cinj.rutgers.edu](mailto:statewide_research@cinj.rutgers.edu).**

Prior to being accepted into the clinical trial, participants are required to undergo a number of tests including bloodwork and a physical exam and meet certain criteria.

Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19

Principal Investigator: Sabiha Hussain, MD, 195 Little Albany St., New Brunswick, NJ, 08903



IRB ID: Pro2020000712  
Approval Date: 4/15/2020  
Expiration Date: 9/26/2020